Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Test of Severe Combined Immunodeficiency (SCID, XLA, SMA)
Test of Severe Combined Immunodeficiency (SCID, XLA, SMA)
Test code:
SU
Test of Severe Combined Immunodeficiency (SCID, XLA, SMA)
Test for SCID disease and SMA.
| Test Code | SU |
|---|---|
| Test Summary | Test for SCID disease and SMA. |
| Turn Around Time | 4 days |
| Acceptable Sample Types | Dried Blood Spots |
| NY Approved | No |
*TAT starts after the sample and all required sample information is received at the processing laboratory.
**The CPT codes listed are in accordance with Current Procedural Terminology, a publication of the American Medical Association, and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party.
This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location.
**The CPT codes listed are in accordance with Current Procedural Terminology, a publication of the American Medical Association, and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party.
This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location.
Test code:
SU
This test is not available in your region United States, please select your nearest laboratory to request more information.
Revvity Sites Globally
Select your location.
Test information
Test description
This test can detect T cell receptor excision ring (TREC), Kappa deletion recombination excision ring (KREC), homozygous deletion of exon 7 of SMN1 gene.
Indications for testing
Newborn screening.
Condition description
Severe combined immunodeficiency (SCID) is a group of rare disorders with pathogenic mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections. Infants with SCID require life-saving treatments. There are several forms of SCID including X-linked and recessive inheritance.
Spinal Muscular Atrophy (SMA) is a group of hereditary diseases that progressively destroys motor neurons. It is one of the most common lethal recessive genetic disorders, and has an incidence of approximately 1/10,000 live births, and an estimated carrier frequency of approximately 1 in 57.
Primary immunodeficiency disorder (PID), X-linked agammaglobulinemia (XLA), commonly caused by a mutation or deletion in the BTK gene which prevents the normal development of B lymphocytes and that results in a severe antibody deficiency, is being considered as a condition. Early diagnosis of PID patients facilitate early treatments, such as stem cell transplantation for SCID or immunoglobulin infusion therapy for XLA, which result in better outcomes.
Spinal Muscular Atrophy (SMA) is a group of hereditary diseases that progressively destroys motor neurons. It is one of the most common lethal recessive genetic disorders, and has an incidence of approximately 1/10,000 live births, and an estimated carrier frequency of approximately 1 in 57.
Primary immunodeficiency disorder (PID), X-linked agammaglobulinemia (XLA), commonly caused by a mutation or deletion in the BTK gene which prevents the normal development of B lymphocytes and that results in a severe antibody deficiency, is being considered as a condition. Early diagnosis of PID patients facilitate early treatments, such as stem cell transplantation for SCID or immunoglobulin infusion therapy for XLA, which result in better outcomes.
Test methods and limitations
Revvity has developed a multiplex real-time PCR assay to allow the screening of infants with severe forms of PID manifested by T and B cell lymphopenia and identify the absence of exon 7 in the SMN1 gene, which is present in approximately 96% of patients with SMA. The assay amplifies four targets in a single PCR reaction; T-cell receptor excision circles (TREC), as a marker of SCID, Kappa-deleting recombination excision circles (KREC), as a marker of XLA, the exon 7 of the SMN1/2 genes, and the RNase P (RPP30) gene, which is used as an internal control and to evaluate the quantity and quality of the DNA extracted from the 3.2 mm punches.
Detailed sample requirements
Dried Blood Spots
| Collection Container(s) |
Dried blood spot card |
|---|---|
| Collection |
Follow kit instructions. Briefly, allow blood to saturate the card until indicated areas are filled and blood has soaked through the card. Air dry the card at ambient temperature for at least 3 hours.
|
| Sample Condition |
Follow the instructions provided with the collection set. Store the dried blood at ambient temperature for up to two days. If the specimen cannot be sent as soon as it is dry, the filter paper should be placed in a sealable plastic bag and stored in a refrigerator (≤ 8°C) or preferably in a freezer. |
| Shipping |
Follow kit instructions. Double bag and ship overnight at ambient temperature. |
How To Order
Step 1
Choose Your Test
Select the correct test for your patient, and download and fill out the Clinical Genomics test requisition form.
Step 2
Collect Sample
Obtain a sample for testing from the patient using one of the provided Revvity Omics test packs.
Step 3
Send Samples
Send samples and all required forms back to Revvity for processing using pre-paid shipping label.
How can we help you?
We are here to answer your questions.
